

Supplementary Table 1. Combination ICI regime by prior ICI agent

Prior ICI Agent	Combination ICI Regime	
	Nivolumab + Ipilimumab	Pembrolizumab + Ipilimumab
Nivolumab	10 (52.6%)	9 (47.4%)
Pembrolizumab	1 (20%)	4 (80%)
Atezolizumab	1 (100%)	0